Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Debt (2021 - 2025)

Historic Total Debt for Ascendis Pharma A (ASND) over the last 5 years, with Q4 2025 value amounting to $948.4 million.

  • Ascendis Pharma A's Total Debt rose 779.85% to $948.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $948.4 million, marking a year-over-year increase of 779.85%. This contributed to the annual value of $920.6 million for FY2025, which is 464.58% up from last year.
  • As of Q4 2025, Ascendis Pharma A's Total Debt stood at $948.4 million, which was up 779.85% from $771.6 million recorded in Q3 2025.
  • Ascendis Pharma A's Total Debt's 5-year high stood at $948.4 million during Q4 2025, with a 5-year trough of $120.1 million in Q4 2021.
  • Moreover, its 5-year median value for Total Debt was $656.5 million (2025), whereas its average is $654.1 million.
  • In the last 5 years, Ascendis Pharma A's Total Debt skyrocketed by 36351.31% in 2022 and then plummeted by 734.3% in 2024.
  • Ascendis Pharma A's Total Debt (Quarter) stood at $120.1 million in 2021, then soared by 363.51% to $556.6 million in 2022, then rose by 6.4% to $592.2 million in 2023, then soared by 48.56% to $879.8 million in 2024, then rose by 7.8% to $948.4 million in 2025.
  • Its last three reported values are $948.4 million in Q4 2025, $771.6 million for Q3 2025, and $684.4 million during Q2 2025.